Primary Article

Spleen Size and Chromosome Analysis as Prognostic Factors in Chronic Myelogenous Leukemia

Authors: ROBERT K. COLLINS MD, JOHN F. JACKSON MD, FRANCIS S. MORRISON MD, EDWARD F. MEYDRECH PhD

Abstract

Of 72 patients with chronic myelogenous leukemia (CML), 37 were Ph1 positive, eight were negative, and 27 were not evaluated for the Ph1 chromosome. Of the 37 patients positive for Ph1, 31 had adequate evaluation. These 31 patients were reviewed for survival with reference to spleen size. Seventeen patients with spleens 3 cm or less below the left costal margin had a 50% survival of 75 months, with a mean survival of 53.9 months. Fourteen patients with spleens greater than 3 cm below the left costal margin had a 50% survival of 21 months, with a mean survival of 19 months (P = .0014). It is concluded that small splenic size in CML is associated with longer survival. It may be that this observation should be taken into consideration when considering splenectomy in the management of patients with CML.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References